Manual/osteopathic/chiropractic techniques
Merciér, J., Midwife, LMT, PhD; Mil er, K., LMT
1Merciér Therapy, Saint Charles, Il inois, USA; 2Sparks Women’s Center, Fort Smith, Arkansas, USA
Among women ages 15–44, 6.7 mil ion have impaired ability to have children, 1.5 mil ion are infertile, and
7.4 mil ion have used infertility services in their lifetime (www.cdc.gov/nchs/fastats/fertile.htm). Now more
than ever, women are having their fertility manipulated by reproductive endocrinology clinics and are
undergoing multiple cycles without knowing the long-term effects of fertility drug use.
Articles have been written about soft tissue abdominal and pelvic work al eviating fertility chal enges, but
no clinical research has been performed. The purpose of this study is to confirm that the use of site-
specific, manual soft tissue therapy is valid as a standalone treatment and with assisted reproductive
technologies to help women become pregnant.
The therapy used in this study is cal ed Merciér Therapy. It involves gentle manipulation of the uterus
and/or massage on a consistent basis—normal y twelve sessions over a one-month period. Merciér
Therapy not only addresses fertility chal enges but also improves soft tissue mobility and breaks down
adhesions to relieve pelvic pain.
Jennifer Merciér, the study’s author, practices in the Chicago area. But those living outside the area can
benefit from her therapy as wel , being treated over a four-day weekend rather than a one-month period.
Merciér also trains licensed professionals in performing Merciér Therapy. Visitto learn more about her technique and training.
Materials and Methods
Forty-eight women ages 28–42 were interviewed and underwent at least two sessions of Merciér Therapy
in Mercier’s clinic in Il inois as well as the coauthor’s office in Arkansas. Both offices are holistic, clinical,
multidisciplinary environments. The women selected for the study al complained of primary and
secondary fertility chal enges regardless of age, current or past pathological condition, prior surgical
intervention, prior treatment, and history of no treatment.
Eighteen women achieved pregnancy within the first six months of their first Merciér Therapy sessions.
Twenty-two women achieved pregnancy within one year of their first Merciér Therapy session. Eight
women did not become pregnant. Of the forty women who became pregnant, thirty-two used Merciér
Therapy as a standalone treatment; six used in-vitro fertilization; two used a combination of Clomid and
intrauterine insemination.
By educating participants about their fertility and cycles and using Merciér Therapy soft tissue
manipulation to increase organ mobility and blood flow while enhancing optimal organ function, women
responded very wel without use of heavy-handed reproductive methods.
Merciér Therapy has proven beneficial in helping couples to achieve pregnancy in a diverse group of
women with various prior assisted reproductive technology backgrounds, ages, races, current
pathologies, and medical histories.
According to the Centers for Disease Control and Prevention, 147,260 assisted reproductive technology
cycles were performed in the United States in 2010; 47,090 live births occurred—31.9%
(www.cdc.gov/art). Why settle for mediocrity? In this study, Merciér Therapy helped 83% of participants
achieve pregnancy; 80% of those women used Merciér Therapy exclusively. When used in conjunction
with medical fertility treatments for the remaining participants, Merciér Therapy shortened the number of
cycles, achieving pregnancy sooner than with fertility treatments alone.
This study reveals that fertility does not need to be medical y manipulated in al cases. Medical fertility
treatments bypass the core problem of poor reproductive organ function. Merciér Therapy creates more
blood flow and mobility of the uterus, ovaries, and tubes, going to the source of the chal enge and helping
to fix it, gently and effectively.
conception, infertility, Merciér Therapy, pregnancy, reproduction, soft tissue manipulation

Source: http://drjennifermercier.com/wordpress/wp-content/uploads/2012/06/abstract11revisedmidwiferytoday.pdf

Microsoft word - wgl_q238_final_e_200114.docx

Working Guidelines Sarah MATHESON and John OSHA, Deputy Reporters General Anne Marie VERSCHUR, Sara ULFSDOTTER and Kazuhiko YOSHIDA Second medical use and other second indication claims Introduction This question seeks to determine the type, scope and enforcement of patent protection for new uses of known chemical compounds when a known substance is found to have a new therapeutic

Ian swallow

IAN SWALLOW HARBOUR STREET MANAGEMENT Tel: 95589005 Fax: 95589006 Email: harbourstreet@optusnet.com.au Age Range: 57 - 67 Weight: 68kgs / 147lbs Eyes: Blue/Grey MEAA: 20011838 Height: 173cm / 5’8” Hair: Brown/Grey www3.showcast.com.au/showcast/67CEE10A TRAINING 2010 Gabriella Maselli McGrail TVC Casting Workshop 2009 Anthony Brandon Yo

Copyright © 2018 Predicting Disease Pdf